Vontobel Holding Ltd. lowered its position in Encompass Health Corporation (NYSE:EHC - Free Report) by 16.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 18,868 shares of the company's stock after selling 3,849 shares during the period. Vontobel Holding Ltd.'s holdings in Encompass Health were worth $2,314,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also added to or reduced their stakes in EHC. Park Avenue Securities LLC boosted its holdings in Encompass Health by 5.7% in the first quarter. Park Avenue Securities LLC now owns 7,123 shares of the company's stock worth $721,000 after acquiring an additional 386 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Encompass Health by 21.5% in the first quarter. GAMMA Investing LLC now owns 2,366 shares of the company's stock worth $240,000 after acquiring an additional 419 shares in the last quarter. SG Americas Securities LLC boosted its holdings in Encompass Health by 737.0% in the first quarter. SG Americas Securities LLC now owns 25,084 shares of the company's stock worth $2,541,000 after acquiring an additional 22,087 shares in the last quarter. Fifth Third Bancorp boosted its holdings in Encompass Health by 88.7% in the first quarter. Fifth Third Bancorp now owns 4,290 shares of the company's stock worth $434,000 after acquiring an additional 2,017 shares in the last quarter. Finally, QRG Capital Management Inc. boosted its holdings in Encompass Health by 2.2% in the first quarter. QRG Capital Management Inc. now owns 15,930 shares of the company's stock worth $1,613,000 after acquiring an additional 341 shares in the last quarter. Institutional investors own 97.25% of the company's stock.
Encompass Health Stock Performance
Shares of EHC opened at $122.02 on Friday. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.76. The company has a market capitalization of $12.29 billion, a price-to-earnings ratio of 23.88, a PEG ratio of 2.14 and a beta of 0.93. The stock has a 50 day moving average of $122.73 and a 200 day moving average of $116.50. Encompass Health Corporation has a 12 month low of $87.85 and a 12 month high of $127.86.
Encompass Health (NYSE:EHC - Get Free Report) last issued its quarterly earnings results on Wednesday, March 16th. The company reported $0.93 EPS for the quarter. The company had revenue of $136.30 million during the quarter. Encompass Health had a return on equity of 17.83% and a net margin of 9.22%. Encompass Health has set its FY22 guidance at $3.83-$4.19 EPS. As a group, sell-side analysts forecast that Encompass Health Corporation will post 4.8 earnings per share for the current year.
Encompass Health Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Wednesday, October 1st will be given a dividend of $0.19 per share. The ex-dividend date of this dividend is Wednesday, October 1st. This is a positive change from Encompass Health's previous quarterly dividend of $0.17. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.6%. Encompass Health's dividend payout ratio (DPR) is 14.87%.
Insider Transactions at Encompass Health
In other Encompass Health news, EVP Patrick William Tuer sold 1,020 shares of the firm's stock in a transaction on Wednesday, August 27th. The stock was sold at an average price of $123.59, for a total value of $126,061.80. Following the completion of the sale, the executive vice president directly owned 18,846 shares of the company's stock, valued at $2,329,177.14. This trade represents a 5.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 2.00% of the stock is owned by corporate insiders.
Wall Street Analyst Weigh In
Several research analysts have issued reports on the company. Weiss Ratings reiterated a "buy (b+)" rating on shares of Encompass Health in a report on Wednesday. Bank of America increased their price objective on Encompass Health from $145.00 to $160.00 and gave the stock a "buy" rating in a research note on Wednesday, September 10th. UBS Group increased their price objective on Encompass Health from $140.00 to $150.00 and gave the stock a "buy" rating in a research note on Thursday, October 2nd. KeyCorp increased their price objective on Encompass Health from $135.00 to $140.00 and gave the stock an "overweight" rating in a research note on Tuesday, September 16th. Finally, Truist Financial increased their price objective on Encompass Health from $135.00 to $140.00 and gave the stock a "buy" rating in a research note on Thursday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $139.86.
Read Our Latest Report on EHC
Encompass Health Company Profile
(
Free Report)
Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Encompass Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Encompass Health wasn't on the list.
While Encompass Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.